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Little is known about long non-coding RNA (lncRNA) related to innate immunity in
lung cancer. The advanced glycosylation end-product specific receptor (AGER)
belongs to the immunoglobulin superfamily, and currently, is the only innate
immune pattern-recognition receptor whose abnormal expression has been
detected in lung cancer. We aimed to explore the lncRNA that is related to
AGER and test its effect on lung carcinogenesis. We selected one lncRNA whose
chromosome location is in close proximity to AGER namely lnc-AGER-1 (defined as
lncAGER). The expression of lncAGER was tested in 276 pairs of lung cancer tissues
and adjacent lung normal tissues, and its correlation with lung cancer clinical
progress was analyzed. A series of assays were further used to assess the biological
function of lncAGER on lung cancer development, tumor immunity and autophagy.
LncAGER expression was moderately correlated with AGER expression (r = 0.360,
P = 2.15 × 10−18) underlying a mechanism that lncAGER upregulates AGER by
competitively binding to miRNA-185. LncAGER was significantly down-regulated in
76.4% of lung cancer tissues compared to adjacent normal tissues due to promoter
hypermethylation. Over-expression of the lncRNA resulted in significant decreases
in proliferation rate, migration ability, colony formation efficiency of lung cancer
cells and tumor growth in nude mice. Notably, lncAGER possibly conduced to
enhancement of cytotoxic effect of THP1. Additionally, the lncRNA also promoted
cell apoptosis by strengthening autophagy. Taken together, these observations
suggest that lncAGER has an inhibitory effect on lung cancer development via
AGER, which may serve as a target for lung cancer treatment.
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Abbreviations: AGER, advanced glycosylation end-product specific receptor; CCK8, cell
counting kit-8; ceRNA, competing endogenous RNA; lncRNA, long non-coding RNA; PPR,
pattern-recognition receptor; TLR, toll-like receptor.
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1 | INTRODUCTION
Lung cancer has been the leading cause of cancer-related deaths for
several years, attributed to about 610 200 deaths in China in 2015 and
expected to be attributed to 155 870 deaths in America in 2017.1,2 In
recent decades, the treatment strategies for lung cancer have
developed greatly, which effectively improved the 5-years’ survival
rate of lung cancer ranging from 8% at 1995-1999 to 18% at 2005-
2009.3 However, there is still a great need for alternative treatment
strategies for treating lung cancer, as the 5-years’ survival rate is below
20%. Immunotherapy is currently a white hope for oncotherapy, yet
emerging data suggests that the immuno checkpoint inhibitors such as
programmed death 1 (PD-1)/programmed death ligand 1 (PD-1/PD-
L1) inhibitors show promise towards improving the survival time of
lung cancer patients.4–6 The Food andDrug Administration (FDA) have
approved two anti-PD-1 monoclonal antibodies for treating lung
cancer, however in response to the therapy, resistance to the drugs has
increasingly been observed.7,8 Thus, further studies towards under-
standing the role of immunity in lung cancer are warranted, given that
limited studies in the area have been undertaken as lung cancer was
historically recognized as a non-immunogenic disease. Finding critical
molecules that modulate immunity in the context of lung carcinogen-
esis would lead to the exploitation of immunotherapeutic agents.
The innate immune system provides the first line of protection
against infectious and non-infectious tissue injury. Environmental
carcinogens such as tobacco can induce lung tissue injury and trigger
the activation of innate immune system through pattern-recognition
receptors (PPRs) including Toll-like receptors (TLRs) and advanced
glycosylation end-product specific receptor (AGER, also named
receptor for advanced glycation end products, RAGE).9 AGER can
recognize endogenous molecules released during chronic inflamma-
tion, a major contributing factor to the pathogenesis of lung cancer.
Notably, it has been shown that pulmonary AGER is required for
allergen-induced innate lymphoid cells accumulation in the lung.10
Further, AGER is one of a limited number of pathogen-recognition
receptors whose expression is altered in lung cancer.11,12 Meanwhile,
analyzing the public data of lung cancer cohorts namely GSE32863
(https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=GSE32863), and GS
E27262 (https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc= GSE27262)
using the GEO2R software, AGER ranks among the top five abnormal
coding genes in lung cancer. But for TLRs, their expressions are normal.
Accumulating evidences show that long non-coding RNAs
(lncRNAs), non-protein coding transcripts longer than 200 nucleotides,
are crucial epigenetic regulators of protein expression and function.
Numerous lncRNAs have been identified as being associated with lung
cancer.13,14 These lncRNAs function as possible oncogenes or tumor
suppressors to promote or dampen lung cancer development through
several pathological mechanisms such as the epithelial-mesenchymal
transition,15 the MAPK signaling pathway.16 However, little is known
about the role of immunity-related lncRNAs in lung cancer.
In the current study, we aimed to explore whether innate
immune related lncRNAs are modulated in the context of lung
carcinogenesis. Given that lncRNAs may exert their biological
functions via regulation of neighbor protein-coding genes, one
lncRNA named lnc-AGER-1 (defined as lncAGER here: http://www.
lncipedia.org/db/gene/lnc-AGER-1); whose chromosome location
(chr6:32,152, 516-32,153,659) is near that of AGER (chr6:32,148,
745-32,152,099), was selected for further investigation in the
context of lung carcinogenesis. LncAGER also named XXbac-
BPG300A18.13 in the UCSC database and is characteristic as a
3prime_overlapping_ncRNA where ditag and/or published experi-
mental data strongly supports the existence of short non-coding
transcripts transcribed from the 3′-untranslated region (3′-UTR).
Our study demonstrated that lncAGER may function to inhibit lung
cancer development, suggesting that it may be utilized as a novel
therapeutic target in the treatment of lung cancer.
2 | MATERIALS AND METHODS
2.1 | Tissue samples
Two hundred and seventy-six lung cancer tissues and adjacent normal
lung tissues were obtained from patients who were diagnosed
pathologically as having primary lung cancer. Among these patients,
182 samples from southern China were collected at the Cancer center
of Guangzhou Medical University and the 1st Affiliated Hospital and
the CancerHospital of KunmingMedical University between 2008 and
2015, the other 94 from eastern China were gathered at the 1st
Affiliate Hospital of Soochow University between 2007 and 2016.
During surgical excision, a portion of putative lung tumor tissues and
adjacent normal lung tissues were immediately isolated from the
excision and placed in liquid nitrogen tank after washed by phosphate
buffer saline (PBS) by a doctor. The sampleswhich considered as tumor
tissues or normal tissues were further determined through pathologic
examination by two pathologists. A written informed consent was
obtained from each patient. The study was approved by the
institutional review board at Guangzhou Medical University and
Soochow University.
2.2 | Cell culture
All cells used in this study were purchased from Cell Bank of Type
Culture Collection of the Chinese Academy of Science (Shanghai
Institute of Cell Biology, Shanghai, China) including nine lung cancer
cell lines (ie, PC9, L78, A549, GLC-82, SBC-5, 95D, NCI-H460, NCI-
H292, and NCI-H1395), four human immortalized lung normal cell
lines (ie, 16HBE, HBE-pic, BEAS-2B, and BEP-2D), human embryonic
kidney cell (HEK-293), and human monocytic leukemic cell line
(THP-1). All cells were cultured in RPMI1640 medium (Gibco, Thermo
Fisher Scientific, Waltham, MA) with the exception of HEK-293 which
were cultured in DMEM and all media was supplemented with 10%
fetal bovine serum (FBS). Cells were placed in a CO2 incubator (SANYO
Electric Co., Ltd., Chuou-ku, Osaka City, Japan) with constant 90%
humidity and 5% CO2. The lung cells were utilized for lncAGER
expression analysis. HEK-293 was used for lentivirus packaging and
production and THP-1 was utilized for co-cultivation assays.
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2.3 | Gene expression detection
The routine SYBR-green quantitative reverse real-time PCR (qRT-PCR)
was performed to assess the expression of lncAGER and AGER in the
276 pairs of lung tissues and 13 cases of lung cell lines with β-actin used
as an internal standard control. The primers for lncAGER were 5′-AAC
CAGGAGGAAGAGGAGGA-3′ (forward) and 5′-TTGGCA AGGTGG
GGT TAT AC-3′ (reverse), for AGER were 5′-CTA CCG AGT CCG TGT
CTA CC-3′ (forward) and 5′-AGT GTG AAG AGC CCT GTC TC-3′
(forward) and forβ-actinwere5′-GGCGGCACCACCATGTACCCT-3′
(forward) and 5′-AGG GGC CGG ACT CGT CAT ACT-3′ (reverse). The
2−ΔCT method was used to demonstrate the expression levels of
lncAGER and AGER. In addition, the standard western blotting analysis
was used to test for the protein expression levels of AGERwith Tubulin
serving as an interval standard control. Notably, the IRDye 800CW-
labeled secondary antibodies (LI-COR, Lincoln, NE) were used in
combination with the LI-COR Odyssey Infrared Imaging System
(LI-COR). Antibodies were purchased from the Abcam Company
(Abcam, Shanghai, China) unless indicated otherwise and all assays
were repeated at least three times. In addition, the expression of AKT1
and ABCC1 were also determined using the qRT-PCR because
they are well-characterized targets of miR-185 involving lung
carcinogenesis.17,18
2.4 | Demethylation treatment with 5-Aza-CdR
On account of that hypermethylation was found to be associated with
decreased expression of AGER in lung cancer tissues,19 we speculated
that promoter methylation may play a role in regulation of both AGER
and lncAGER expression. Total 1 × 105 PC9 cells were seeded in a
24-well culture plate and treated with the DNA demethylating agent
5-aza-2-deoxy-cytidine (5-Aza-CdR) at concentrations of 0, 0.5, 2,
10 µmol/L for 72 h. Then the cells were collected and prepared for the
qRT-PCR analysis to determine lncAGER and AGER expression.
2.5 | MassARRAY® quantitative methylation analysis
The MassARRAY® Quantitative Methylation Analysis was conducted
to determine promoter methylation level of lncAGER and AGER in 15
pairedDNA samples from lung cancer tissues and adjacent normal lung
tissues by a commercial company (Biomiao Biological Technoiogy,
Beijing, China). As cpgplot (http://www.ebi.ac.uk/Tools/seqstats/
emboss_cpgplot/) shows no CpG island in promoter region of both
lncAGER and AGER, promoter regions with high density CG sites in
lncAGER (−868 to −1313 bp relative to transcriptional start site) and
AGER (−984 to −1584 bp relative to transcriptional start site) were
tested. The Agena EpiDesigner was used to designed primers for
lncAGER as “forward: aggaagagagGAAGGTTTTTAAATTTGTGTGT
GG” and “reverse: cagtaatacgactcactatagggagaaggctACTCCTATTA-
CAACCTCCCAACTTC”; for AGER as “forward:aggaagagagATTTTTG-
GATAGAGGATATGGGTTA” and “reverse: cagtaatacgactcactataggga
gaaggctAACAAACCCTTCACTACCTCCAC”. The methylation rate was
calculated from15 pairs of lung cancer and adjacent normal tissues and
the frequency of methylation level was defined as the average
methylation rate of tumor or normal tissues.
2.6 | Construction of the lentivirus vector of
lncAGER and infection
The full-length complementary DNA (cDNA) of human lncAGER was
synthesized by iGeneBio Co, Ltd (Guangzhou, China). The cDNA was
then cloned into the lentivirus vector pEZ-Lv201. The lncAGER vector
or the empty vector were transfected into HEK-293 to collect viral
particles. The viral particles were then used to infect two lung cancer
cell lines, PC9 and L78, which express extremely low lncAGER
followed by qRT-PCR to analyze the expression of lncAGER to
determine the infection success rates. Cells expressing the correct
levels of lncAGER were used for further studies. Cells that were
infected with empty pEZ-Lv201 particles were used as control cells.
2.7 | MicroRNA mimics treatment and luciferase
assay
Given that bioinformatics analysis (http://www.mirbase.org/index.
shtml, http://www.microrna.org/microrna/getMirnaForm.do) showed
that lncAGER may function as a competing endogenous RNA (ceRNA)
to promote AGER expression by binding to microRNAs miRNA-4688-
5p, miRNA-3171, miRNA-185, and miRNA-182, the mimics or
inhibitors of these microRNAs were synthesized and transiently co-
transfected with the Psi-CHECK2 luciferase reporter containing the
3′-UTR of AGER into the PC9 and L78 cell lines. Luciferase activity that
is defined as renilla luciferase data normalized to firefly luciferase data
was then determined using the Dual-Luciferase Reporter Assay
System (Promega, Beijing, China). Independent triplicate experiments
were performed using each microRNA. In addition, the two cell lines
were also directly treated with the miRNA-185 mimics to determine
the effect of microRNA on AGER expression. The suppression rate of
AGER expression was calculated by the ratio of AGER protein level
following miR-185 treatment minus normal AGER protein level to
normal AGER protein level.
2.8 | Subcellular fractionation
To establish the subcellular localization of lncAGER, cytosolic and
nuclear fractions were isolated using the nuclear/cytoplasmic isolation
kit (Biovision, San Francisco, CA). Following total RNA extraction from
the cytosolic and nuclear fractions, gene expression analysis was
performed by the qRT-PCR.
2.9 | Tumor cell viability and proliferation assay in
vitro
The cell counting kit-8 (CCK8) assay, plate colony and soft-agar colony
forming experiments were performed to assess the effect of lncAGER
on viability and proliferation of PC9 and L78 cells, in accordance with
themanufacturer's protocols. In the CCK8 assay, cells were cultured in
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a 96-well plate with 1000 cells per well and the cell viability was
monitored after 24, 48, 72, and 96 h. In the plate colony experiment,
the cells were plated in a 6-well plate at a density of 1000 cells each
group and cultured for two weeks. After stained with Giemsa, the
visible colonies were counted (The whole plate was divided into nine
sub-boxes and total clones were counted in settled six representative
fields). In the soft-agar experiment, the lower layer agar contained
5mL of 0.75% low melting agar in RPMI-1640 medium with 10% FBS,
while the upper second layer containing 0.35% agar dissolved in RPMI-
1640 medium with 10% FBS in a 60mm dish. When solidified, the
upper layer was injected with 1000 cells. After cultured for 3 wk, the
dishes were stained with 0.04% crystal violet (Sigma, Guangzhou,
China) and the colonies were counted (The whole plate was divided
into 16 sub-boxes and total clones were counted in settled eight
representative fields). All trials were conducted at least three times.
2.10 | Flow cytometry analysis
The flow cytometry analysis was used to establish whether lncAGER
had an effect on cell cycle and apoptosis. For cell cycle analysis, PC9
and L78 cell lines were labeled with propidium iodide (PI) (7sea-
pharmtech, Shanghai, China). For analysis of apoptosis, the Annexin V-
fluorescein isothiocyanate/7-Aminoactinomycin D (FITC/7-AAD)
apoptosis kit was used according to the manufacturer's construction
(MULTISCIENCES, Hangzhou, China).
2.11 | Tumor cell migration and invasion assay
An 8-µm Transwell chamber (Costar, Corning Incorporated, Corning,
NY) without or with matrigel-coated was used to test cell migration and
invasion of the PC9 and L78 cell lines. The protocols were performed in
accordance with our previously published studies.20 Briefly, 1.0 × 105
cells were plated on Transwell chambers with 20mg Matrigel™ or
uncoated. The lower chamber contained medium with 10% FBS which
served as the chemoattractant. Non-invading or non-migrated cells
were removed with cotton swabs, and migrated or invaded cells were
counted (total cells were counted in randomly selected twenty
representative fields). Each experiment was performed in triplicate.
2.12 | Tumor growth in vivo
ThePC9andL78cell lineswerediluted toaconcentrationof1 × 106cells/
mL in phosphate buffer (PBS). Then, 0.2mL of the cell solution (2 × 105
cells) were subcutaneously injected into BALB/c nude mice (n = 5 per
group). Thevolumeof tumorwascalculatedas length ×width2 × 0.5.After
24days, themicewereeuthanizedand the lungsolid tumorswere isolated
for pathological section analysis. The expression of AGER and lung tumor
morphology were investigated by immunohistochemical staining and
morphometric technique using established routine procedures. In scoring
AGER protein expression, the Image Pro Plus software was used to
measure staining intensity score following the standard protocol.
Percentage of positive cells examined was scored as 0 (negative), 1
(<10%), 2 (11-50%), 3 (51-80%), and 4 (>80%) by two independent
pathologists. The relative AGER expression was defined as the intensity
score multiplying the percentage score.
2.13 | Co-culture of monocyte and lung cancer cells
To explore the possible role of lncAGER on tumor immunology, PC9 or
L78 cell line was co-cultured with the humanmonocyte cell line THP-1
(ie a suspension cell line, effector cells). THP-1 cells were initially
seeded with a concentration of 2 × 105 cells/mL per well in a 96-well
plate. After 24 h, either PC9 or L78 cells were added to eachwell (1000
cells per well, targeted cells). The lung cells were also independently
cultured and served as control groups. After 24 h, the cell supernatants
(in the presence/absence of THP-1 cells) and lung cancer cells were
collected to determine optical density (OD) using the CCK8 assay. The
cytotoxic activity of THP1 was calculated as follows:21
Cytotoxicity ¼ 1 ODeffector cellsþ target cellsð Þ  ODeffector cellsð Þ
ODtarget cells
as suggested:
2.14 | Autophagy detection
Autophagy is known as programmed type II cell death, which plays an
essential role in development, organization, and functions of the
immune system. Defects in autophagy lead to several diseases,
including cancer and autoimmunity.22 Here, autophagy level was
determined in terms of the ratio between LC3-II protein expression
and LC3-I protein expression. The routine western blotting analysis
was used to test for the protein expression levels of both LC3-II and
LC3-I with Tubulin serving as an interval standard control.
2.15 | Statistical analysis
The paired t-test was used to assess the differences in gene expression
and frequency of methylation level between lung cancer tissues and
adjacent lung normal tissues. The student's t-test and one-way Anova
test were applied for analyzing the differences in quantitative data
between two groups. The Pearson correlation analysis was performed
to analyze correlation between two the quantitative data. All tests
were two-sided by using the Stata 12.0 software and P-value less than
0.05 was considered to be statistically significant.
3 | RESULT
3.1 | LncAGER is down-regulated in lung cancer
Both the Coding Potential Calculator (http://cpc.cbi.pku.edu.cn/)
and the Coding-Potential Assessment Tool (http://lilab.research.
bcm.edu/cpat/index.php) strongly suggested that lncAGER has no
coding probability. As shown in Figure 1A, the expression of
lncAGER was significantly lower in lung cancer tissues when
compared to adjacent lung normal tissues in southern samples
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(mean ± standard deviation: 0.29 ± 0.53 vs 0.70 ± 0.79;
P = 8.51 × 10−8), eastern samples (0.19 ± 0.52 vs 0.27 ± 0.51;
P = 0.006) and total samples (0.26 ± 0.53 vs 0.57 ± 0.69;
P = 1.52 × 10−8); 76.4% (211/276) of the lung cancer samples
showing a downregulation of lncAGER. A similar trend was also
observed in lung cell lines when compared to normal cells wherein
the normal cells showed higher lncAGER than the cancer ones
(Figure 1B). In addition, the lentiviral vector carrying lncAGER was
successfully constructed and high expression of lncAGER in both the
PC9 and L78 cells was evident (Figure S1a). In addition, the
expression of AGER was significantly down-regulated in cancer
tissues compared to their adjacent normal tissues (P < 0.001;
Figure S1b-d), which are concordant with previously published
studies.11,12 The demographics and clinical feathers of studied
patients are listed in Table 1.
3.2 | LncAGER expression is correlated with T status
The expression status of lncAGER was classified as “High” or “Low” on
the basis of whether or not owing to the expression of lncAGER in lung
tissues upon in adjacent lung normal tissues. As listed in Table 2,
patients with advanced T status (3 + 4) exerted significantly more low
status of lncAGER expression than those with early T status (1 + 2) in
southern samples (15.4% vs 31.7%; P = 0.033). The difference was
towards a margin at the edge of significance in eastern samples (22.4%
vs 48.9%; P = 0.061). When merged the two populations, low
expression of lncAGER was associated with risk of advanced T status
(P = 0.002). However, there was no other notable association between
lncAGER expression and other variables.
3.3 | LncAGER enhances AGER expression via
binding to miR-185
Both PC9 and L78 expressed a relevant portion of lncAGER in
cytoplasm (Figure 1C), indicating a role of lncAGER as a post-
transcriptional factor. The cells that overexpressed lncAGER
showed a significantly higher level of AGER expression than that
of control cells at both mRNA and protein levels (Figures 1D and
1E). Meanwhile, the expression of lncAGER was positively
correlated with that of AGER in lung cancer tissues (r = 0.383,
FIGURE 1 Expression status of lncAGER and AGER and their correlation in lung tissues. (A) The qRT-PCR was performed to assess the
expression of lncAGER in lung tissues from southern samples (left), eastern samples (middle) and total samples (right). Bar height corresponds
to the log mean difference between tumor tissues and normal tissues from three technical replicates. P, calculated by the paired t-test. (B)
The expression of lncAGER in lung cancer and normal cell lines. (C) Subcellular localization of lncAGER expression. (D) The qRT-PCR was
conducted to determine AGER mRNA expression. Bar height corresponds to the mean, and error bars represent SD for three biological or
technical replicates. **P < 0.01, calculated by the student's t-test. (E) The western blot was conducted to determine AGER protein level. (F)
The correlation between lncAGER expression and AGER expression in lung cancer tissues (left), in adjacent normal lung tissues (middle) and in
total lung tissues (right). Purple dot corresponds to log lncAGER expression in x axis and log AGER expression in y axis. P, calculated by the
Pearson correlation analysis
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P = 3.82 × 10−11), normal tissues (r = 0.292, P = 3.82 × 10−7), and in
total tissues (r = 0.360, P = 2.15 × 10−18; Figure 1F). Further
analyses showed that lncAGER may regulate AGER expression by
binding to miRNA-185. Bioinformatic analysis predicted that 4
microRNAs are expressed in both PC9 and L78 cells (Figure S2a)
and of these, the luciferase assay showed that miR-185 (Figure 2A),
but not miR-182, miR-3171, or miR-4688-5p (Figure S2b-d) could
possibly bind to 3′-UTR of AGER, as that miR-185 mimics
significantly weakened the luciferase activity, while the inhibitors
enhanced it (P < 0.05 for all). The miR-185 mimics caused
significantly less reduction of luciferase activity in both cells
overexpressed lncAGER than control cells, but the inhibitors
resulted in non-significant increase between the up-regulated and
control cell lines (Figure 2B). Further, following treatment of PC9 or
L78 cells with the miR-185 mimics, the AGER protein expression
was not suppressed to the same level in cells overexpressing
lncAGER when compared to control cells (Figure 2C).
3.4 | LncAGER prevents suppression effect of miR-
185 on AKT1 and ABCC1
Following treatment of PC9 cells with the miR-185 mimics or mock
mimics, miR-185 apparently did not alter expressions of both AKT1
and ABCC1 in cells overexpressing lncAGER unlike what it did in
control cells to significantly suppress the expression of two genes
(Figures 2D and 2E). Noticeably, expressions of both AKT1 and ABCC1
were still down-regulated in cells overexpressing lncAGER when
compared to control cells.
TABLE 1 The demographics and clinical feathers of studied lung cancer patients
Characteristic Southern samples N (%) Eastern samples N (%) Pearson χ2 P-value
Total 182 (65.9) 94 (34.1)
Age
<60 105 (57.7) 51 (54.3) 0.298 0.585
≥60 77 (42.3) 43 (45.7)
Gender
Female 52 (28.6) 28 (29.8) 0.045 0.833
Male 130 (71.4) 66 (70.2)
Family tumor history
No 161 (88.5) 84 (89.4) 0.050 0.822
Yes 21 (11.5) 10 (10.6)
Smoking
No 67 (36.8) 30 (31.9) 0.653 0.419
Yes 115 (63.2) 64 (68.1)
Stage
I + II 71 (39.0) 29 (30.9) 1.786 0.181
III + IV 111 (61.0) 65 (69.1)
T
1 + 2 104 (57.1) 45 (47.9) 2.145 0.143
3 + 4 78 (42.9) 49 (52.1)
N
0 76 (41.8) 57 (60.6) 2.332 0.127
1 + 2 + 3 106 (58.2) 37 (39.4)
M
0 135 (74.2) 65 (69.1) 1.427 0.232
1 47 (25.8) 29 (30.9)
Histological classification
Adenocarcinoma 86 (47.3) 41 (43.6) 0.735 0.692
Squamous carcinoma 51 (28.0) 31 (33.0)
Other typesa 45 (24.7) 22 (23.4)
aLarge cell carcinoma, small cell carcinoma, and hybrid or undifferentiated carcinoma.
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3.5 | Promoter methylation directly contributes to
decreased lncAGER but not AGER expression
After treatment of PC9 cells with 5-Aza-CdR, lncAGER expression
increased sequentially along with increase of 5-Aza-CdR concentra-
tion (P = 0.012; Figure 2F). A similar trend was observed on AGER
expression. However, the effect was not significant (P = 0.704;
Figure S3a). The MassARRAY further showed that cancer tissues
harbored a significantly higher methylation level at promoter region of
lncAGER than normal tissues (Figure 2G). However, no significant
difference was observed for AGER (Figure S3b, c). Moreover, the
average methylation level of lncAGER promoter was negatively
correlated with lncAGER expression (P = 0.004; Figure 2H).
3.6 | LncAGER inhibits proliferation and tumor
growth of lung cancer cells
Using the CCK8 assay, it was shown that the proliferation of cells
expressing lncAGER was significantly lower when compared to the
control groups (Figure 3A). Similarly, both the plate colony and soft-
agar experiments showed that the up-regulation of lncAGER impaired
the tumorigenesis abilities of both the PC9 and L78 cell lines in vitro
(Figures 3B and 3C). The findings were corroborated with our in vivo
work which showed that lncAGER inhibited tumorigenesis in nude
mice. As shown in Figure 3D, the tumors were smaller and slower to
develop in mice, which were injected with the cells that over-
expressed lncAGER when compared to control cells. Meanwhile, the
TABLE 2 Associations between the expression of lncAGER and clinical feathers as well as demographics among lung cancer patients





















<60 80 (76.2) 25 (23.8) 0.738 33 (64.7) 18 (35.3) 0.967 113 (72.4) 43 (27.6) 0.769
≥60 57 (74.0) 20 (26.0) 28 (65.1) 15 (34.9) 85 (70.8) 35 (29.2)
Gender
Female 40 (76.9) 12 (23.1) 0.744 16 (57.1) 12 (42.9) 0.305 56 (70.0) 24 (30.0) 0682
Male 97 (74.6) 33 (25.4) 45 (68.2) 21 (31.8) 142 (72.4) 54 (27.6)
Family tumor history
No 119 (73.9) 42 (26.1) 0.238 53 (63.1) 31 (36.9) 0.290 172 (70.2) 73 (29.8) 0.111
Yes 18 (85.7) 3 (14.3) 8 (80.0) 2 (20.0) 26 (83.9) 5 (16.1)
Smoking
No 52 (77.6) 15 (22.4) 0.577 18 (60.0) 12 (40.0) 0.496 70 (72.2) 27 (27.8) 0.908
Yes 85 (73.9) 30 (26.1) 43 (67.2) 21 (32.8) 128 (71.5) 51 (28.5)
Stage
I + II 47 (66.2) 24 (33.8) 0.111 15 (51.7) 14 (48.3) 0.219 62 (62.0) 38 (38.0) 0.057
III + IV 90 (81.1) 21 (18.9) 46 (70.8) 19 (29.2) 136 (77.3) 40 (22.7)
T
1 + 2 71 (68.3) 33 (31.7) 0.033 23 (51.1) 22 (48.9) 0.061 94 (67.6) 45 (32.4) 0.002
3 + 4 66 (84.6) 12 (15.4) 38 (77.6) 11 (22.4) 104 (81.9) 23 (18.1)
N
0 46 (69.7) 20 (30.3) 0.188 23 (53.5) 20 (46.5) 0.891 69 (63.3) 40 (36.7) 0.166
1 + 2 + 3 91 (78.4) 25 (21.6) 28 (54.9) 23 (45.1) 119 (71.3) 48 (28.7)
M
0 97 (75.2) 32 (24.8) 0.969 41 (68.3) 19 (31.7) 0.353 138 (73.0) 51 (27.0) 0.488
1 40 (75.5) 13 (24.5) 20 (58.8) 14 (41.2) 60 (69.0) 27 (31.0)
Histological classification
Adenocarcinoma 62 (72.1) 24 (27.9) 0.640 29 (70.7) 12 (29.3) 0.239 91 (71.7) 36 (28.3) 0.741
Squamous
carcinoma
40 (78.4) 11 (21.6) 21 (67.7) 10 (32.3) 61 (74.4) 21 (25.6)
Other typesa 35 (77.8) 10 (22.2) 11 (50.0) 11 (50.0) 46 (68.7) 21 (31.3)
aLarge cell carcinoma, small cell carcinoma, and hybrid or undifferentiated carcinoma.
Bold font indicates significant difference.
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pathological characteristics of tumor were more obvious in the latter
than the former (Figure 3E). In addition, the tumor tissues originated
from overexpressed lncAGER cells expressed higher AGER than that
originated from the control cells (Figure 3F).
3.7 | LncAGER suppresses cell migration, but not
invasion
As shown in Figure 4A, the ability of PC9 cells to migrate was impaired in
cells which over-expressed lncAGER (P = 0.026), however, the invasion
ability throughMatrigel™ remainedunchangedwhencompared tocontrol
cells (P = 0.732; Figure 4B). We failed to detect the ability to migrate and
invade of L78 cells because no cells pass through the Boyden chambers.
3.8 | LncAGER affects cell cycle and apoptosis
The flow cytometry data showed that the overexpression of lncAGER
induced more cells arrest at G0/G1 phase and concomitantly fewer
cells at the S phase of cell cycle when compared to control cells
(Figure 4C). Also, higher rates of apoptosis were evident in cells which
overexpressed lncAGER when compared to the control cells
(Figure 4D).
FIGURE 2 Regulatory mechanisms of lncAGER on expression of target genes and lncAGER down-regulation. (A) The luciferase assay was
conducted to determine effect of miR-185 on 3′-UTR of AGER in PC9 and L78 cells. R/F: Renilla luciferase data normalized to firefly
luciferase data. (B) The luciferase assay in lncAGER overexpression cells and control cells of PC9 and L78. (C) AGER protein level in lncAGER
overexpression cells and control cells of PC9 and L78 following treatment of miR-185 mimics. The suppression rate of AGER expression was
calculated by the ratio of AGER protein level following miR-185 treatment minus normal AGER protein level to normal AGER protein level. (D
and E) Expression of AKT1 (D) and ABCC1 (E) in lncAGER overexpression cells and control cells of PC9. (F) Expression of lncAGER in PC9
cells following 5- Aza-CdR treatment. Bar height corresponds to the mean, and error bars represent SD for three biological or technical
replicates. P-value was calculated by the student's t-test or oneway Anova test. (G) Methylation analysis by the MassARRAY. Left: Circle
indicates methylation level of each CG site. The darker the color represents the higher the methylation rate (left). Methylation level was
calculated from 15 pairs of lung cancer and adjacent normal tissues and the frequency refers to the average methylation rate of tumor or
normal tissues (right). P-value was calculated by the paired t-test. (H) Correlation between average methylation level of 7 CG sites and
lncAGER expression. P-value was calculated by the Spearman rank correlation analysis. *P < 0.05, **P < 0.01, ***P < 0.001
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3.9 | LncAGER possibly actives autophagy
As AGER has been reported to affect autophagy,23 herein we asked
whether the lncAGER has a similar function. Levels of autophagy, as
indicated by an enhanced LC3-II/LC3I ratio, were significantly higher in
PC9 and L78 cells which overexpressed lncAGER when compared to
the corresponding control cells (Figure 5A), suggesting that lncAGER
may modulate autophagy in these cells.
3.10 | LncAGER has a possible effect on THP-1
induced tumor cytotoxicity
When co-incubated with THP-1 cells, the results showed that over-
expression of lncAGER significantly boosted THP-1's cytotoxic activity
against PC9or L78 cellswhen compared to control cells (P < 0.01 for both
cells; Figure 5B). Further, significantly more increases in apoptosis
proportion were exhibited in PC9 or L78 cells overexpression lncAGER
FIGURE 3 Biological effects of lncAGER on tumor growth of lung cancer. Both PC9 and L78 cells were transfected with pEZ-Lv201-
lncAGER (lncAGER-OE) and empty pEZ-Lv201 (empty-NC). (A) The CCK8 assay was conducted to determine the proliferation of PC9 and L78
cells. Circle dot on line corresponds to the mean, error bars represent SD for seven biological replicates. (B and C) The plate colony (B) and
soft-agar experiments (C) were conducted to test for tumorigenicity of PC9 and L78 cells. Bar height corresponds to the mean, and error bars
represent SD for three biological replicates. (D and E) The BALB/c nude mice was used to determine the growth of tumor, originating
injection of PC9 and L78 cells. Tumor volume was measured every three days, until the end of third week (D). Circle dot on line corresponds
to the mean, error bars represent SD for four biological replicates. The tumor grew on the mouse (E, left), extracted tumor tissues from the
mouse (E, middle) and pathological section of tumor tissues were (E, right) imaged. (F) The immunohistochemical staining was conducted to
determine the protein expression of AGER. Horizontal line in box corresponds to the mean, error bars represent SD for six technical
replicates. *P < 0.05, **P < 0.01, calculated by the student's t-test
PAN ET AL. | 313
FIGURE 4 Biological effects of lncAGER on cell migration, invasion, cell cycle and apoptosis. (A and B) The Transwell assay was conducted
to determine the cell migration (A) and invasion with MatrigelTM coated (B) of PC9 cells. Midcourt line corresponds to the mean, error bars
represent SD for three biological replicates. (C) The flow cytometry was conducted to determine the cell cycle of PC9 and L78 cells. (D) The
flow cytometry was conducted to determine the cell apoptosis of PC9 and L78 cells. Bar height corresponds to the mean, and error bars
represent SD for three biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, calculated by the Student's t-test
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than control cells (PC9: 12.5%vs2.3%, L78: 13.5%vs9.9%;Pvaluesequal
to 3.00 × 10−4 and 0.041, respectively; Figure 5C).
4 | DISCUSSION
Although many lncRNAs have been linked with lung cancer develop-
ment, little is known about their roles in tumor immunology. In the
current study, we revealed lncAGER modulates the expression of
AGER, a critical innate immune PRR, and that it plays a pivotal role in
lung cancer. LncAGER is down-regulated in lung cancer tissues owing
to hypermethylation and its low expression is correlated with
advanced T status in lung cancer patients. Mechanistically, our study
shows that lncAGER impairs lung cancer development by affecting
proliferation, apoptosis, the cell cycle and lung tumor cell migration.
FIGURE 5 Biological effects of lncAGER on autophagy and tumor cytotoxicity of THP-1. (A) The western blot was conducted to determine
the expression of LC3-I and LC3-II, the ratio of which indicates the autophagy level in PC9 and L78 cells. (B) The CCK8 assay was conducted
to determine the proliferation of PC9 and L78 cells co-cultured with THP1. (C) The flow cytometry was conducted to determine the cell
apoptosis of PC9 and L78 cells co-cultured with THP1. Bar height corresponds to the mean, and error bars represent SD for three biological
or technical replicates. *P < 0.05, **P < 0.01, ***P < 0.001, calculated by the Student's t-test
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Furthermore, our study suggests that lncAGER may also functionally
conduces to cytotoxic activity of immunologic effector cells and
promoted autophagy. Importantly, to our knowledge, our study is the
first to explore the role on innate-immune related lncRNAs in lung
cancer development.
The lncAGER is a 656 bp transcript without protein-coding
potency. It is located on chromosome 6p21.32 (chr6:32152516-
32153659), 417 bp upstream to the AGER gene. The 6p21.32 is an
identified susceptible region of lung cancer in different ethnicities.24–
26 Accumulation evidences demonstrated that AGER is related to lung
cancer, a pathology that is intimately linked with the innate immune
system and inflammation.11,12 Specifically, it has been shown that
AGER is down-regulated or absent during lung carcinogenesis.11,12
Further, GEO chip data (GSE32863, GSE27262) showed that AGER
ranks among the top five abnormal coding genes in lung cancer.
Further, in contrast as most cancer types wherein AGER expression is
up-regulated,27–36 in the present study, we also found that AGER was
down-regulated in the lung cancer tissues used herein. While AGER is
expressed in innate immune cells to enable the recognition of allergens
and to active innate immune responses, it is also expressed in epithelial
cell such as those which are present in the pulmonary tissue to enable
innate immune cells recruitment.27,37,38 Notably, genetic variants in
the AGER gene have been reported to be associated with lung cancer
risk in a Chinese population.39,40 Together, these studies suggest that
AGER may play a role in anti-lung oncogenesis.
In the current study, we found that lncAGER exerted an
inhibitory action on carcinogenesis, similar to that exhibited by
AGER. We found that lncAGER was down-regulated owing to high
lever methylation in lung cancer and that the low-expression of
lncAGER was correlated with advanced T status. The 5-Aza-CdR
treatment could restore lncAGER expression. Hypermethylation in
upstream of AGER has been reported to be associated with
decreased AGER expression.19 On account of lncAGER is located at
upstream of AGER, based on our findings, we hold the opinion that
this hypermethylation first causes reduced lncAGER expression
and followed by AGER decrease owing to lncAGER regulation.
Over-expression of lncAGER significantly inhibited cell prolifera-
tion of lung cancer cells. LncAGER also induced cell cycle arrest at
G0/G1 phase with fewer cells in the S phase, suggesting that
lncRNA impairs cell division. Also, we showed that lncAGER
promoted cell apoptosis. Specially, ectopic lncAGER expression is
sufficient to inhibit migration but not invasion of lung cancer cells.
Unlike migration referring motile ability, cell invasion defines the
ability of cells to become motile and to navigate through the
extracellular matrix within a tissue or to infiltrate neighbouring
tissues. This process needs gene expression changes causing
proteolysis and degradation of the matrix,41 which apparently fail
to achieve by lncAGER. Cell invasion is close to cancer metastasis
and needs synthesis and secretion of degradation enzymes. This
may be why lncAGER expression correlates with T but not N and M
in patients.
Furthermore, lncAGER possibly modulates the anti-tumor activi-
ties of monocytic THP1 cells wherein the co-cultivation experiments
demonstrated that the up-regulation of lncAGER effectively enhanced
FIGURE 6 Proposed functional action of lncAGER in modulating lung cancer development. Promoter methylation causes decreased
LncAGER expression in lung cancer and promotes lung cancer development by downregulating AGER expression, resulting in inactivation of
anti-tumor immunity and autophagy, both of which accelerate progress of lung cancer
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the cytotoxic effects of THP1. LncAGER may also promote autophagy
as that the autophagy level was increased in response to lncAGER up-
regulation. However, additional experiments are required to further
explore the role of lncAGER on innate immunity and autophagy.
We propose that lncAGER exerts its inhibitory role on lung
cancer in part due to effects on AGER. Underlying the ceRNA
mechanism, we propose that lncAGER acts as a miR-185
sequestrate and thereby increases the expression of AGER. MiR-
185 has been demonstrated to target AGER in esophageal
squamous cell carcinomas.33 Here, miR-185 was consistently
found to target on AGER in lung cancer. Controversially, miR-
185 is an identified tumor suppressor of several cancers,42–46
which has been reported to be involved in chemo-resistance of
lung cancer.17 Further, miR-185 has been discovered to target
AKT1 and ABCC1 to inhibit lung genesis and progression.17,18
Here, lncAGER also prevents suppression effect of miR-185 on
AKT1 and ABCC1 as same as what it had done on AGER, suggesting
that lncAGER has reciprocal effect on lung carcinogenesis.
Inconceivably, both AKT1 and ABCC1 were reversely down-
regulated in ectopic lncAGER cells when compared to control cells.
This is really confused but probable. It is plausible to speculate that
by sponging other microRNAs or regulatory mechanism, lncAGER
might also affect expression of other protein coding genes that
may have regulatory effect on AKT1 and ABCC1 expression.
Anyway, our findings confirm that lncAGER exerts an integrated
effect playing as an inhibitory role on lung cancer.
In summary, our present study revealed that lncAGER is down-
regulated in lung cancer. Upregulation of lncAGER can inhibit lung
cancer proliferation and migration, induce cell cycle arrest at G0/G1
phase and promote apoptosis. LncAGER also functions in a manner
similar to that of its target, AGER, to possibly facilitate tumor
immunity and autophagy via up-regulation of AGER by sponging
miR-185 (Figure 6). Taken together, these data demonstrate that
lncAGER plays an inhibitory role in lung oncogenesis and may be a
druggable target or as a drug towards the curtailment of lung
cancer.
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